474
Participants
Start Date
July 16, 2015
Primary Completion Date
April 4, 2018
Study Completion Date
July 28, 2020
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
St Vincent'S Uni Hospital; Medical Oncology, Dublin
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Chemotherapie & Infektionskrankhei, Vienna
Freiburger Spital; Onkologie, Fribourg
Herlev Hospital; Afdeling for Kræftbehandling, Herlev
Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed, Odense C
Haukeland Universitetssjukehus; Klinisk forskningspost, Bergen
LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz
Aarhus Universitetshospital; Kræftafdelingen, Aarhus N
Kantonsspital St. Gallen; Onkologie/Hämatologie, Sankt Gallen
Columbia University Medical Center, New York
Memorial Sloan Kettering, New York
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Uniklinik-Eppendorf; Zentren F. Innere Medizin-Klinik U. Poliklinik, Hamburg
Trakya University Medical Faculty, Edirne
Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona
Institut Bergonie, Bordeaux
Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul
Prof. Dr. Cemil Tascioglu City Hospital; Med Onc, Istanbul
Sarah Cannon Cancer Center and Research Institute, Nashville
The Cleveland Clinic Foundation, Cleveland
Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica, Siena
Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie, Trier
Universitatsklinik Heidelberg; Universitätshautklinik und Nationales Centrum für Tumorerkrankungen, Heidelberg
Centre Leon Berard; Departement Oncologie Medicale, Lyon
Hopital Saint Louis, Service D Oncologie Medicale, Paris
MD Anderson Cancer Center, Houston
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli
Institut Gustave Roussy, Villejuif
Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy, Moscow
S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint Petersburg
INCA 1- Instituto Nacional de Câncer X, Rio de Janeiro
Hospital das Clinicas - UFRGS, Porto Alegre
Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo
BCCA-Vancouver Cancer Centre, Vancouver
University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto
Helsinki University Central Hospital; Dept of Oncology, Helsinki
St James' Hospital; Cancer Clinical Trials Office, Dublin
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam
Erasmus MC, Rotterdam
Universitair Medisch Centrum Utrecht, Utrecht
Oslo Universitetssykehus HF; Radiumhospitalet, Oslo
Centrum Onkologii w Bydgoszczy, Bydgoszcz
Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdansk
Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Now. Tkanek Miekkich,Kosci i Czer., Warsaw
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona
Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara
Clatterbridge Cancer Centre, Bebington
Southampton General Hospital; Medical Oncology, Southampton
Hoffmann-La Roche
INDUSTRY